Epernicus: Dan Peer, Ph.D.

Dan Peer, Ph.D.

Position:
Senior Lecturer

Cell Research & Immunology

Center for Nanoscience and Nanotechnology

Tel Aviv University (Tel Aviv, Israel)
Degrees:

Ph.D., Biophysics, Tel Aviv University (Tel Aviv, Israel)
Past Advisors:

Motomu Shimaoka (as Post Doctoral Fellow)

Rimona Margalit (as Graduate Student - Ph.D.)
Research:
Selective targeting and reprograming of leukocytes

Our lab is studying how to manipulate cells’ functions in order to generate novel therapeutic strategies to treat inflammatory diseases and cancers. We are combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques to develop innovative therapeutics to target specific cells within the immune system. In addition, we are developing nanomedicines by designing highly selective targeting moieties and novel nanocarriers, with an ultimate goal to translate some of our findings into clinical settings.
Other Experience:
2005-2008 Postdoctoral fellow - Immune Disease Institute, Harvard Medical School

Communities:

Dan Peer's Genealogy

The Adobe Flash Player plugin (version 8) is required to view the genealogy tree.
Download the plugin here.

Dan Peer's Publications (16)

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice.
Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D, Habiro K, Yang YG, Manjunath N, Shimaoka M, Shankar P

Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Feb;18(2):370-6
RNAi nanoparticles in the service of personalized medicine.
Kedmi R, Peer D

Nanomedicine (London, England). 2009 Dec;4(8):853-5
Systemic siRNA delivery to leukocyte-implicated diseases.
Peer D, Shimaoka M

Cell cycle (Georgetown, Tex.). 2009 Mar 15;8(6):853-9
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen.
Argov M, Kashi R, Peer D, Margalit R

Cancer letters. 2009 Feb 8;274(1):118-25
Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins.
Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, Shimaoka M

Blood. 2008 Dec 15;112(13):5007-15
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M

Science (New York, N.Y.). 2008 Feb 1;319(5863):627-30
Corneal gene therapy.
Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV

Journal of controlled release : official journal of the Controlled Release Society. 2007 Dec 20;124(3):107-33
Nanocarriers as an emerging platform for cancer therapy.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R

Nature nanotechnology. 2007 Dec;2(12):751-60
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.
Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M

Proceedings of the National Academy of Sciences of the United States of America. 2007 Mar 6;104(10):4095-100
AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes.
Shimaoka M, Kim M, Cohen EH, Yang W, Astrof N, Peer D, Salas A, Ferrand A, Springer TA

Proceedings of the National Academy of Sciences of the United States of America. 2006 Sep 19;103(38):13991-6
Fluoxetine and reversal of multidrug resistance.
Peer D, Margalit R

Cancer letters. 2006 Jun 18;237(2):180-7
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D, Dekel Y, Melikhov D, Margalit R

Cancer research. 2004 Oct 15;64(20):7562-9
Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models.
Peer D, Margalit R

International journal of cancer. Journal international du cancer. 2004 Feb 20;108(5):780-9
Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D, Margalit R

Neoplasia (New York, N.Y.). 2004 Jul-Aug;6(4):343-53
Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes.
Peer D, Florentin A, Margalit R

Biochimica et biophysica acta. 2003 May 2;1612(1):76-82
Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes.
Peer D, Margalit R

Archives of biochemistry and biophysics. 2000 Nov 15;383(2):185-90

One Figure

Selective targeting of siRNAs (red) into activated lymphocytes (green)using fusion protein that target conformation-selective integrin LFA-1. Naive cells (not stained) do not uptake siRNAs.

Join Epernicus (membership is free)

Epernicus is open to current and former research scientists.

Already a member?
Sign in to view Dan's full profile.

Dan Peer, Ph.D.

Senior Lecturer

Selective targeting and reprograming of leukocytes

Dan Peer's Genealogy

Dan Peer's Publications (16)

One Figure